[\$87, 22: 2003 | 3:01FM | | 856 792-6773 | FOLEY AND LARDNER

Attorney Docket No.: 087714/0113

Application No.: 09/424,951
Filing Date: January 20, 2000
Response to Office Action (Paper No. 28)

Page 2 of 7

## Amendments to the Claims

Please amend claims 1, 14 and 15 as indicated below in the listing of claims. Please cancel claims 3, 13 and 17-19 without prejudice.

## Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

- (Currently amended) An isolated polynucleotide that <u>sneedes codes for a protein that is</u> linked to phenotypic switching in Candida albicans and that <u>exhibits 70% or greater overall sequence</u> <u>[deptity to SEO ID No.3 hybridizes, under stringent conditions, to the polynucleotide sequence of SEQ ID No. 1, wherein said protein displays kiness activity.
  </u>
- (Previously presented) A polynucleotide according to claim 1, comprising the sequence of SEO ID No. 3.
  - (Cancelled).
- (Previously presented) A method of screening for a compound with the ability to inhibit expression or functionality of the CaNIK1 protein comprising:
- (A) contacting a yeast cell that exhibits phenotypic switching with a test substance, wherein said yeast cell comprises:
  - (i) a polynucleotide according to claim 1 and
- a promoter operably linked to said polynucleotide, such that said yeast cell produces a protein encoded by said polynucleotide; then
- (B) monitoring the ability of said test substance to inhibit expression or functionality of said protein encoded by said polynucleotide in said yeast cell.
- (Previously presented) The method according to claim, wherein step (B) comprises monitoring the level of said protein produced in said cell.

Application No.: Filing Date:

09/424,951 January 20, 2000 Attorney Docket No.: 087714/0113

Response to Office Action (Paper No. 28)

Page 3 of 7

(Previously presented) The method according to claim 4, wherein step (B) comprises monitoring the level of mRNA encoded by said polynucleotide and produced by said cell.

- (Previously presented) The method according to claim , wherein step (B) comprises monitoring the level of kinase activity within said yeast cell, wherein said kinase activity typifies said protein.
- (Previously presented) The method according to claim & wherein a promoter is operably linked to a reporter gene and wherein step (B) comprises monitoring the level of transcription of said reporter gene within said yeast cell.
- (Previously presented) The method according to claims, wherein step (B) comprises offecting a two-dimensional gel electrophoresis.
- (Previously presented) The method according to claim &, wherein step (B) comprises effecting a Northern blot, a primer extension, or a ribonuclease protection assay.
  - (Previously presented) The method according to claim, wherein step (B) comprises:
  - (A) labeling ATP with 12P in vitro:
  - (B) running cellular proteins on a polyacrylamide gel; and
  - (C) determining the amount of <sup>32</sup>P labeled protein using autoradiography.
- (Previously presented) The method according to claim, 8, wherein said reporter gene is a luciferase gene and luciferase activity is monitored using a luminometer.
  - 13. (Cancelled).
- (Currently amended) The polynucleotide of claim 1 13 that exhibits 80% or greater identity to SEQ ID NO 3.
- (Currently amended) The polynucleotide of claim 1 13 that exhibits 90% or greater identity to SEO ID NO 3.

09/424,951

Attorney Docket No.: 087714/0113

Application No.: January 20, 2000 Filing Date: Response to Office Action (Paper No. 28) Page 4 of 7

SEQ ID. NO 4.

(Previously presented) An isolated polynucleotide encoding the amino acid sequence of

17.-19. (Cancelled).

(Previously presented) A culture of a bacterial strain containing the lambda phage